Personalized Cancer Chemotherapy : An Effective Way of Enhancing Outcomes in Clinics.

Front Cover -- Personalized Cancer Chemotherapy: An Effective Way of Enhancing Outcomes in Clinics -- Copyright -- Contents -- List of figures and tables -- Figures -- Tables -- About the author -- Preface -- References -- List of abbreviations -- 1 - Introduction -- References -- 2 - Drug sensitivity testing -- 2.1 History of drug sensitivity testing -- 2.2 Methodology of drug sensitivity testing [6-7] -- 2.3 Comparison between in vivo and in vitro drug sensitivity testing methodologies [6-7] -- 2.4 Relationship of drug responses in drug chemosensitivity testing and clinical tumor treatment -- 2.5 Possible reasons for unsatisfactory survival rates in spite of using drug sensitivity testing -- 2.6 Cytotoxic and cytostatic anti-cancer drugs? -- 2.7 Conclusion -- References -- 3 - Individualized cancer chemotherapy via cancer biomarkers or bioinformatics detection -- 3.1 Cancer biomarkers and cancer bioinformatics for ICC [1-3] -- 3.2 Seeing is predicting -- 3.3 New challenges -- 3.4 Discussion -- 3.5 Other considerations -- 3.6 Mathematical modeling and computational networks as assistant systems -- 3.7 Finding tumorigenic markers from the genome to predict anticancer drug responses -- 3.8 Future directions -- References -- 4 - Pharmacogenetics -- 4.1 Background -- 4.2 Introduction -- 4.3 Architectural framework of an anticancer drug pharmacogenetics or pharmacogenomics study -- 4.4 Examples -- 4.5 Discussion -- References -- 5 - Individualized antimetastatic therapy [1-2] -- 5.1 Background -- 5.2 Will antimetastatic therapy differ from antiproliferative therapy? -- 5.3 Therapeutic mechanisms of the current antimetastatic drugs -- 5.4 Drawbacks of current clinical antimetastatic therapy -- 5.5 Should human tumor metastasis be treated according to clinical situations -individualized antimetastatic therapy? [19,21-22].

5.6 Find more metastatis-related molecules and develop novel types of antimetastatic drugs -- 5.7 Targeting formed metastatic foci in clinics -- 5.8 Discussion -- 5.9 Conclusion -- References -- 6 - Drug combinations -- 6.1 Introduction -- 6.2 Cytotoxic drugs and biotherapy -- 6.3 The advantages of a strategy of combining cytotoxic anticancer drugs and biotherapy -- 6.4 Combined use of both antiproliferative drugs (primary tumor) and antimetastatic drugs -- 6.5 Combined cytotoxic drugs and cytostatic drugs -- 6.6 Rules of drug combination -- 6.7 Conclusion -- References -- 7 - Assistant chemotherapy -- 7.1 Anti-thrombosis therapy -- 7.2 Antidepressant therapy -- 7.3 Improving patients' physiological conditions -- 7.4 Conclusion -- References -- 8 - Cost-effectiveness considerations -- 8.1 Background -- 8.2 Routine cost of cancer chemotherapy -- 8.3 Calculation of cost-effectiveness -- 8.4 The keys to the study of cost-effectiveness in individualized cancer chemotherapy -- 8.5 Future trends -- 8.6 Conclusion -- References -- 9 - Discussion -- 9.1 Drug sensitivity testing -- 9.2 The development of cancer biomarker detection -- 9.3 Pharmacogenetics or pharmacogenomics -- 9.4 Antimetastatic therapy -- 9.5 Should antimetastatic drugs be offered to all cancer patients? -- 9.6 Drug combinations -- 9.7 Assistant therapies -- 9.8 Overall considerations -- References -- 10 - Conclusion -- References.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.